We are studying the safety and effects of givinostat in boys aged 2 to under 6 years with Duchenne Muscular Dystrophy. This trial aims to understand how the drug works in their bodies and its impact on muscle function.
Health conditions and diseases that the clinical trial is designed to study and treat.
Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle weakness and degeneration, primarily affecting boys. It is caused by mutations in the dystrophin gene, leading to difficulties in movement and mobility.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
